A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.

Date Issued
2018
Author(s)
Seufferlein, Thomas
Lausser, Ludwig
Prager, Gerald W.
Kasper, Stefan
Niedermeier, Michael
Müller, Lothar
Kubicka, Stefan
Buechner-Steudel, Petra
Wille, Kai
Perkhofer, Lukas
Hann, Alexander
Berger, Andreas Wolfgang
Arnold, Dirk
Kestler, Hans
Ettrich, Thomas Jens
DOI
10.1200/JCO.2018.36.15_suppl.e15545